COVID-19 With Convalescent Plasma

Southeast University, China

Status: Completed

Conditions: COVID-19 Convalescent Plasma Treatment

Treatments: Biological: convalescent plasma

Study type: Observational

Funder types: Other

Identifiers

NCT04616976

COVID-19 convalescent plasma

Details and patient eligibility

About

To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.

Enrollment: 78 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. > 18 years of age;
2. laboratory-confirmed diagnosis of COVID-19;
3. respiratory failure requiring advanced respiratory support (i.e. high flow nasal cannula[HFNC], noninvasive mechanical ventilation [NIV], and invasive mechanical ventilation [IMV]).

Exclusion criteria

• no

Trial design

78 participants in 2 patient groups

convalescent plasma therapy group

Description:

the patients received convalescent plasma therapy

Treatment:

Biological: convalescent plasma

Control group

Description:

the patients with similar situation without convalescent plasma therapy